494 related articles for article (PubMed ID: 36827874)
21. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
Mariottini A; Bertozzi A; Marchi L; Di Cristinzi M; Mechi C; Barilaro A; Massacesi L; Repice AM
J Neurol; 2022 Jun; 269(6):2840-2847. PubMed ID: 35239006
[TBL] [Abstract][Full Text] [Related]
22. Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption.
Gröning R; Dernstedt A; Ahlm C; Normark J; Sundström P; Forsell MNE
Front Immunol; 2023; 14():1219560. PubMed ID: 37575257
[TBL] [Abstract][Full Text] [Related]
23. Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study.
Alfonso-Dunn R; Lin J; Lei J; Liu J; Roche M; De Oliveira A; Raisingani A; Kumar A; Kirschner V; Feuer G; Malin M; Sadiq SA
Front Immunol; 2023; 14():1194671. PubMed ID: 37449202
[TBL] [Abstract][Full Text] [Related]
24. Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment.
Woopen C; Dunsche M; Haase R; Raposo C; Pedotti R; Akgün K; Ziemssen T
Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36224045
[TBL] [Abstract][Full Text] [Related]
25. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
Smith JB; Gonzales EG; Li BH; Langer-Gould A
JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
[TBL] [Abstract][Full Text] [Related]
26. Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy.
Priddey A; Chen-Xu MXH; Cooper DJ; MacMillan S; Meisl G; Xu CK; Hosmillo M; Goodfellow IG; Kollyfas R; Doffinger R; Bradley JR; Mohorianu II; Jones R; Knowles TPJ; Smith R; Kosmoliaptsis V
Front Immunol; 2023; 14():1296148. PubMed ID: 38259440
[TBL] [Abstract][Full Text] [Related]
27. Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.
Gadani SP; Reyes-Mantilla M; Jank L; Harris S; Douglas M; Smith MD; Calabresi PA; Mowry EM; Fitzgerald KC; Bhargava P
EBioMedicine; 2021 Nov; 73():103636. PubMed ID: 34666226
[TBL] [Abstract][Full Text] [Related]
28. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
Louapre C; Ibrahim M; Maillart E; Abdi B; Papeix C; Stankoff B; Dubessy AL; Bensa-Koscher C; Créange A; Chamekh Z; Lubetzki C; Marcelin AG; Corvol JC; Pourcher V;
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):24-31. PubMed ID: 34341142
[TBL] [Abstract][Full Text] [Related]
29. Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis.
Satyanarayan S; Safi N; Sorets T; Filomena S; Zhang Y; Klineova S; Fabian M; Horng S; Tankou S; Miller A; Krieger S; Lublin F; Sumowski J; Katz Sand I
Mult Scler Relat Disord; 2022 Jun; 62():103737. PubMed ID: 35533419
[TBL] [Abstract][Full Text] [Related]
30. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483
[TBL] [Abstract][Full Text] [Related]
31. The humoral response to SARS-COV-2 vaccines in MS patients: A case series exploring the impact of DMT, lymphocyte count, immunoglobulins, and vaccine type.
Jakubecz C; Zhang XS; Woodson S; Serra A; Abboud H
Mult Scler Relat Disord; 2022 May; 61():103785. PubMed ID: 35381535
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.
Katz Sand I; Gnjatic S; Krammer F; Tuballes K; Carreño JM; Satyanarayan S; Filomena S; Staker E; Tcheou J; Miller A; Fabian M; Safi N; Nichols J; Patel J; Krieger S; Tankou S; Horng S; Klineova S; Beck E; Merad M; Lublin F
Mult Scler Relat Disord; 2023 Feb; 70():104486. PubMed ID: 36628884
[TBL] [Abstract][Full Text] [Related]
33. Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis.
Nemeth D; Vago H; Tothfalusi L; Ulakcsai Z; Becker D; Szabo Z; Rojkovich B; Merkely B; Nagy G
Front Immunol; 2022; 13():960001. PubMed ID: 36311767
[TBL] [Abstract][Full Text] [Related]
34. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.
Tallantyre EC; Scurr MJ; Vickaryous N; Richards A; Anderson V; Baker D; Chance R; Evangelou N; George K; Giovannoni G; Harding KE; Hibbert A; Ingram G; Jolles S; Jones M; Kang AS; Loveless S; Moat SJ; Robertson NP; Rios F; Schmierer K; Willis M; Godkin A; Dobson R
Mult Scler Relat Disord; 2022 Aug; 64():103937. PubMed ID: 35700625
[TBL] [Abstract][Full Text] [Related]
35. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
Front Immunol; 2021; 12():781843. PubMed ID: 34956211
[TBL] [Abstract][Full Text] [Related]
36. Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.
Novak F; Nilsson AC; Nielsen C; Holm DK; Østergaard K; Bystrup A; Byg KE; Johansen IS; Mittl K; Rowles W; Mcpolin K; Spencer C; Sagan S; Gerungan C; Wilson MR; Zamvil SS; Bove R; Sabatino JJ; Sejbaek T
Mult Scler Relat Disord; 2021 Nov; 56():103251. PubMed ID: 34571415
[TBL] [Abstract][Full Text] [Related]
37. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
[TBL] [Abstract][Full Text] [Related]
38. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
Tortorella C; Aiello A; Gasperini C; Agrati C; Castilletti C; Ruggieri S; Meschi S; Matusali G; Colavita F; Farroni C; Cuzzi G; Cimini E; Tartaglia E; Vanini V; Prosperini L; Haggiag S; Galgani S; Quartuccio ME; Salmi A; Repele F; Altera AMG; Cristofanelli F; D'Abramo A; Bevilacqua N; Corpolongo A; Puro V; Vaia F; Capobianchi MR; Ippolito G; Nicastri E; Goletti D;
Neurology; 2022 Feb; 98(5):e541-e554. PubMed ID: 34810244
[TBL] [Abstract][Full Text] [Related]
39. B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study.
Conte WL
Mult Scler Relat Disord; 2022 Jan; 57():103413. PubMed ID: 35158480
[TBL] [Abstract][Full Text] [Related]
40. T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers.
Iannetta M; Landi D; Cola G; Malagnino V; Teti E; Fraboni D; Buccisano F; Grelli S; Coppola L; Campogiani L; Andreoni M; Marfia GA; Sarmati L
Mult Scler Relat Disord; 2021 Oct; 55():103157. PubMed ID: 34418737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
